OncoTherapy Science (FRA:30O) Other Current Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
49 GF Score
Price €0.09
GF Value €0.07
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Other Current Receivables?

OncoTherapy Science FRA:30O +6.06% 49 Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:30O with a GF Score™ of 49/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 1 warning sign investors should review.

OncoTherapy Science's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

OncoTherapy Science Other Current Receivables Related Terms

OncoTherapy Science Other Current Receivables Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Other Current Receivables Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:30O
49GF Score
OncoTherapy Science Inc FRA:30O
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
OncoTherapy Science (FRA:30O) has a Other Current Receivables of €0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Other Current Receivables too high?
OncoTherapy Science's current Other Current Receivables is €0.00 Mil. Overall, OncoTherapy Science has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Other Current Receivables compare to VRTX and REGN?
OncoTherapy Science's Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.09 — trading 25% above its estimated fair value. The current Other Current Receivables is €0.00 Mil. OncoTherapy Science's overall GF Score™ is 49/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Other Current Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of €0.09 is trading 25% above its estimated GF Value™ of €0.07. GuruFocus considers OncoTherapy Science to be Fairly Valued.

Key valuation signals for FRA:30O:

  • Other Current Receivables: €0.00 Mil
  • GF Value™: €0.07 vs. price of €0.09 (25% above fair value)
  • GF Score™: 49/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
49GF Score

Get the complete analysis for FRA:30O

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.09
Price
€0.07
GF Value